New findings from the BBSRC strategically-funded Institute of Food Research, are providing insights into the interaction between bacteria and mucins, proteins which form mucus, and how these interactions affect our health.
Dr Nathalie Juge and her team at the IFR have shown that the ability to use mucins in the human gut varies between different gut bacteria strains. Their study was published in the journal PLOS ONE.
We live in a symbiotic relationship with trillions of bacteria in our gut. They help us digest food, prime our immune system and keep out pathogens. In return we provide a suitable environment for them to grow, including a layer of mucus that coats the gut lining. Mucus is formed from proteins called mucins that have sugars associated with them. These form a diverse and complex range of structures. Mucins provide attachment sites and a source of nutrition for some bacteria, but not all species are allowed to take advantage of this. The complexity of the sugar structures in the mucins is thought to be how our bodies specify which bacteria can set up home, but exactly how this works isn’t yet known.
The IFR researchers looked at Ruminococcus gnavus. This is a common species of gut bacteria found in over 90% of people, including infants just a few days old. It has also been implicated in gut-related health conditions. A number of studies have shown that patients suffering from Inflammatory Bowel Diseases have a disproportionate representation of R. gnavus.
This study looked at two different R. gnavus strains. Although both R. gnavus strains can use mucins, only one had the ability to survive when mucins were the sole source of food.
Comparing the genomes of the R. gnavus strains identified gene clusters used to breakdown mucins.
Differences in these genes explain the different abilities of the strains to use mucins. The mucin sugar structures change in different parts of the gut and over time, suggesting the strains may be adapted for different environments or to colonise us at different times.
For example, the R. gnavus strain adapted to survive solely on mucins may give it the ability to colonise the guts of newborn babies, when mucins represent the only sources of sugars for bacteria. In adults, the strains of bacteria that degrade mucins are the ones most likely to contact the cells underneath the mucus and so these strains are the ones most likely to influence health.
A better understanding of which strains use mucins and exactly how they do this will give us new insights into what makes a healthy gut bacteria population, and how fluctuations from this might link to gut diseases like Crohn’s disease and ulcerative colitis.
Notes to editors
Reference: ‘Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent’ Crost, E. H. et al doi: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0076341 was published by PLOS ONE on Friday October 25 2013
This study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Royal Society. Emmanuelle Crost was a recipient of a Newton International Fellowships-2009.
About the IFR
The mission of the Institute of Food Research, www.ifr.ac.uk ,is to undertake international quality scientific research relevant to food and human health and to work in partnership with others to provide underpinning science for consumers, policy makers, the food industry and academia. It is a company limited by guarantee, with charitable status.
IFR is one of eight institutes that receive strategic funding from the Biotechnology and Biological Sciences Research Council. IFR received a total of £12.7M investment from BBSRC in 2012-13.
The institutes deliver innovative, world class bioscience research and training, leading to wealth and job creation, generating high returns for the UK economy. They have strong links with business, industry and the wider community, and support policy development
The institutes’ research underpins key sectors of the UK economy such as agriculture, bioenergy, biotechnology, food and drink and pharmaceuticals. In addition, the institutes maintain unique research facilities of national importance